Daxor Corporation sees substantial growth in revenue, new customer acquisitions, and strategic agreements
From GlobeNewswire: 2025-03-04 08:05:00
Daxor Corporation, the global leader in blood volume measurement technology, has issued a corporate update in a Letter to Shareholders from CEO & President, Michael Feldschuh. The company reported substantial progress in revenue growth, new customer acquisitions, and strategic agreements, among other achievements. Financial highlights include a net asset value increase to $36,789,893 as of December 31, 2024, and revenue growth of 116.5% year on year for 2024. The company has also made advancements in the development of its next generation blood volume analyzer system and has entered into strategic acquisitions to expand its product offerings.
The operating division of Daxor Corporation has achieved cash-flow break even in Q1 of 2025, with revenue increasing over 100% year on year for the first 2 months. The company has signed new accounts and received funding awards from organizations like the DoD and NIH. Daxor’s next-gen analyzer has completed testing data requested by the FDA and is set for resubmission. Acquisition agreements have been made to bring manufacturing in-house for certain products, with plans for new product launches in the future. The focus remains on advancing healthcare through optimal fluid management with blood volume analysis.
Read more at GlobeNewswire: Daxor Corporation CEO and President Michael Feldschuh